Azacitidine filed for myelodysplastic syndrome in Japan
This article was originally published in Scrip
Nippon Shinyaku has filed an approval application in Japan for azacitidine (NS-17) for the treatment of myelodysplastic syndrome (MDS). The product, licensed from Pharmion (now part of Celgene), is already marketed in around 20 countries, including in the US as Vidaza.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.